Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., . . . Vaduganathan, M. (2024). Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation (New York, N.Y.), 149(6), 450. https://doi.org/10.1161/CIRCULATIONAHA.123.067584
Chicago-Zitierstil (17. Ausg.)Neuen, Brendon L., et al. "Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria." Circulation (New York, N.Y.) 149, no. 6 (2024): 450. https://doi.org/10.1161/CIRCULATIONAHA.123.067584.
MLA-Zitierstil (9. Ausg.)Neuen, Brendon L., et al. "Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria." Circulation (New York, N.Y.), vol. 149, no. 6, 2024, p. 450, https://doi.org/10.1161/CIRCULATIONAHA.123.067584.